Xoma Has Acquired An Economic Interest In Three Women's Health Assets From Daré Bioscience For An Upfront Payment Of $22M
Xoma Has Acquired An Economic Interest In Three Women's Health Assets From Daré Bioscience For An Upfront Payment Of $22M
Xoma以2200萬美元的預付款從DaréBioscience手中收購了三項女性健康資產的經濟權益
- Organon, a global women's healthcare company, initiated XACIATO commercial activities in the fourth quarter of 2023.
- XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in two additional women's health assets: Ovaprene, an investigational potential first-in-category Phase 3 hormone-free monthly intravaginal contraceptive, and Sildenafil Cream, 3.6%, a potential first-in-category Phase 3-ready candidate for female sexual arousal disorder.
- Bayer HealthCare holds the exclusive rights to U.S. commercialization of Ovaprene.
- XOMA provided $22 million upfront as non-dilutive royalty capital solution to Daré Bioscience.
- 全球女性醫療保健公司Organon於2023年第四季度啓動了XACIATO的商業活動。
- XOMA進一步擴大了其後期產品組合，通過合成特許權使用費和另外兩項女性健康資產的里程碑式權益：Ovaprene，一種潛在的3期無激素月用****內避孕藥Ovaprene和西地那非乳膏，佔3.6％，是女性性喚起障礙的潛在第三階段候選藥物。
- 拜耳醫療擁有Ovaprene在美國商業化的專有權。
- XOMA向達瑞生物科學提供了2200萬澳元的預付特許權使用費資本解決方案，作爲非稀釋性特許權使用費資本解決方案。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間